Advanced search
Publication Cover
Leukemia & Lymphoma Volume 60, 2019 - Issue 5
Submit an article Journal homepage
385
Views
15
CrossRef citations to date
0
Altmetric
Letter to the Editor

Phase II trial of Lestaurtinib, a JAK2 inhibitor, in patients with myelofibrosis

John MascarenhasIcahn School of Medicine at Mount Sinai, Tisch Cancer Institute, New York, NY, USA; Correspondence[email protected]
ORCID Iconhttp://orcid.org/0000-0002-8400-0483View further author information
ORCID Icon,
Maria R. BaerGreenebaum Cancer Center, University of Maryland, Baltimore, MD, USA; View further author information
,
Craig KesslerLombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washinton, DC, USA; View further author information
,
Elizabeth HexnerAbramson Cancer Center, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA; View further author information
,
Douglas TremblayIcahn School of Medicine at Mount Sinai, Tisch Cancer Institute, New York, NY, USA; ORCID Iconhttp://orcid.org/0000-0003-2584-6953View further author information
ORCID Icon,
Leah PriceDepartment of Population Health, New York University, New York, NY, USA; View further author information
,
Lonette SandyIcahn School of Medicine at Mount Sinai, Tisch Cancer Institute, New York, NY, USA; View further author information
,
Rona WeinbergNew York Blood Center, Myeloproliferative Disorders Laboratory, New York, NY, USA; View further author information
,
Heike PahlSection of Molecular Hematology, Department of Hematology/Oncology, University Medical Center Freiburg, Freiburg, Germany; View further author information
,
Lewis R. SilvermanIcahn School of Medicine at Mount Sinai, Tisch Cancer Institute, New York, NY, USA; View further author information
,
Judith D. GoldbergDepartment of Population Health, New York University, New York, NY, USA; View further author information
,
Heidi KosiorekDivision of Biostatistics, Mayo Clinic Arizona, Scottsdale, AZ, USAView further author information
,
Amylou C. DueckDivision of Biostatistics, Mayo Clinic Arizona, Scottsdale, AZ, USAView further author information
&
Ronald HoffmanIcahn School of Medicine at Mount Sinai, Tisch Cancer Institute, New York, NY, USA; View further author information
 show all
Pages 1343-1345 | Received 10 Sep 2018, Accepted 29 Sep 2018, Published online: 22 Jan 2019

References

  • Levine RL, Loriaux M, Huntly BJ, et al. The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia. Blood. 2005;106:3377–3379.
  • Verstovsek S, Mesa RA, Gotlib J, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med. 2012;366:799–807.
  • Harrison C, Kiladjian JJ, Al-Ali HK, et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med. 2012;366:787–798.
  • Mascarenhas J, Hoffman R. A comprehensive review and analysis of the effect of ruxolitinib therapy on the survival of patients with myelofibrosis. Blood. 2013;121:4832–4837.
  • Hexner EO, Serdikoff C, Jan M, et al. Lestaurtinib (CEP701) is a JAK2 inhibitor that suppresses JAK2/STAT5 signaling and the proliferation of primary erythroid cells from patients with myeloproliferative disorders. Blood. 2008;111:5663–5671.
  • Santos FP, Kantarjian HM, Jain N, et al. Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis. Blood. 2010;115:1131–1136.
  • Hexner EO, Mascarenhas J, Prchal J, et al. Phase I dose escalation study of lestaurtinib in patients with myelofibrosis. Leuk Lymphoma. 2015;56:2543–2551.
  • Barosi G, Bordessoule D, Briere J, et al. Response criteria for myelofibrosis with myeloid metaplasia: results of an initiative of the European Myelofibrosis Network (EUMNET). Blood. 2005;106:2849–2853.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.